Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases?

This work is a literature review, presenting the current state of the use of cannabinoids on neurodegenerative diseases. The emphasis is on Parkinson’s (PD) and Alzheimer’s (AD) diseases, the two most prevalent neurological diseases. The review goes from Cannabis sativa and its hundreds of bioactive compounds to Δ9-tetrahydrocannabinol (THC) and mainly cannabidiol (CBD) and their interactions with the endocannabinoid receptors (CB1 and CB2).

Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial

Evidence suggests cannabidiol (CBD) has anxiolytic properties, indicating potential for novel treatment strategies. However, few clinical trials of CBD-based products have been conducted, and none thus far have examined the impact of these products on cognition.

An Observational, Longitudinal Study of Cognition in Medical Cannabis Patients over the Course of 12 Months of Treatment: Preliminary Results

Cannabis use has increased dramatically across the country; however, few studies have assessed the long-term impact of medical cannabis (MC) use on cognition. Studies examining recreational cannabis users generally report cognitive decrements, particularly in those with adolescent onset. As MC patients differ from recreational consumers in motives for use, product selection, and age of onset, we assessed cognitive and clinical measures in well-characterized MC patients over 1 year. Based on previous findings, we hypothesized MC patients would not show decrements and might instead demonstrate improvements in executive function over time.

Medical cannabis and cognitive performance in middle to old adults treated for chronic pain

Authors: Sharon R Sznitman, Simon Vulfsons, David Meiri, Galit Weinstein Published in Drug and Alcohol Review September 2020 Abstract Introduction and aims: Cannabis exposure is becoming more common in older…

Association Between Recent Cannabinoid Use and Acute Ischemic Stroke

Author: Carmela V. San Luis, Christa O’Hana S. Nobleza, Shashank Shekhar, Rebecca Sugg, Darren J. Villareal, Tapan Mehta, Shreyas Gangadhara Published in Frontiers in Psychology June 2020 Abstract Objectives Studies that…

Totality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and Critical Review

Author: Ciara A. Torres, Christopher Medina-Kirchner, Kate Y. O’Malley, and Carl L. Hart Published in Frontiers in Psychology May 2020 Abstract Background Despite limited data demonstrating pronounced negative effects of prenatal…

Effects of Δ9-tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological FMRI study.

Authors: Matthijs G. Bossong, Gerry Jager, Hendrika H. van Hell, Lineke Zuurman, et al
Journal of Cognitive Neuroscience, March 2012

Deficits in memory function are an incapacitating aspect of various psychiatric and neurological disorders. Animal studies have recently provided strong evidence for involvement of the endocannabinoid (eCB) system in memory function. Neuropsychological studies in humans have s…

Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study.

Authors: Igor Grant, Raul Gonzalez, Catherine L. Carey, Loki Natarajan, Tanya Wolfson
Journal of the International Neuropsychological Society, July 2003

The possible medicinal use of cannabinoids for chronic diseases emphasizes the need to understand the long-term effects of these compounds on the central nervous system. We provide a quantitative synthesis of empirical research pertaining to the non-acute (residual) effects of…